[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. - Wikidata - wikimedia - TriplyDB

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

http://www.wikidata.org/entity/Q37210960

about

Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics Development of Companion Diagnostics First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.Mechanisms underlying 18F-fluorodeoxyglucose accumulation in colorectal cancer Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET Therapeutic options for the management of pancreatic cancer.North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.Systematic analysis of 18F-FDG PET and metabolism, proliferation and hypoxia markers for classification of head and neck tumors Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues.Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?Statins impair glucose uptake in tumor cells An Oncogenic Virus Promotes Cell Survival and Cellular Transformation by Suppressing Glycolysis Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.The Emerging Hallmarks of Cancer Metabolism Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: an overview Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer (18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer.FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.GLUT1 as a therapeutic target in hepatocellular carcinoma.Control of nutrient stress-induced metabolic reprogramming by PKCζ in tumorigenesis.Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.Conceptual framework for cutting the pancreatic cancer fuel supply.Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma.Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer.Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis.Metastatic Renal Cancer: What Role for Everolimus?Canonical and new generation anticancer drugs also target energy metabolism.FDG PET/CT imaging as a biomarker in lymphoma.Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.

P2860

Q26740567-02D76ED6-7A1C-4DE3-AA98-9F627BA4612F Q26766292-D013FBD7-1C45-4B83-8455-D5D453703548 Q26774670-0F6E21A1-C0B3-4DE2-97B0-EEBF55456FD7 Q27853088-81630CF3-884B-4391-81AC-8AF33BB48EDC Q28067736-5A485498-88DC-4C1F-8E55-785D1DEBAEA5 Q33396217-9DE3433D-F128-4CCE-984E-6F2C48D348A2 Q33706877-2557ACB7-83F5-438E-A7D2-8369F961611C Q33730033-C07BE1CA-689B-4FB9-B39E-DF804EC81A8A Q33760578-86A58CE8-450E-4A7A-A3AF-34855728817F Q34041370-89EC8B5A-D006-4F52-9426-E9A3FAF66EBD Q34093776-E59715C9-6FF9-4928-9D9A-197DFD750774 Q34441838-A2FA6C6B-4295-4E40-B139-295A2470F9F9 Q35103263-207B816B-828A-480A-8541-E53E5903E2CD Q35169825-AD749691-8958-4299-A1BD-4B75D022472E Q35567261-C2CF8DAA-714F-420F-92FC-F846B1D4C1E5 Q35584486-B3E0B6C9-F76A-4269-AC0D-44356BCFFBBC Q35584938-9E5F8D4C-1853-496D-95E0-9DA7AED5E499 Q35660948-BC3EB406-FEFC-4DA5-B4E8-DBAD21A168B0 Q35879814-4DD0E498-C986-4922-95D6-85AE80E93E50 Q35949773-53405267-FE44-43D0-B449-8F4F727264A0 Q36019773-A3D800F1-1FD8-4679-AA29-7C1EE80804EA Q36200547-2040A37A-B705-4081-A0E8-E14B005D8C14 Q36468964-026039BB-0D52-4AA6-91BD-850B570AC624 Q36533822-465191F5-EF1A-4664-8466-2622BCB3EB5D Q36694518-322259C7-7B0B-4071-97FA-5D6984A287C0 Q36801971-471EAFC1-CE5D-41A0-AECC-AF50D9C3A0B2 Q37082453-99AB8089-6BE9-4794-B4D7-6796D7AA51D1 Q37236032-A6D52E04-39BF-4471-BAED-3D649825F4AD Q37236275-6F517E77-B00C-416E-981A-176EC7C52231 Q37623840-2240CA55-1907-4ADE-B513-13F30FEF55E1 Q37659446-A3703534-EAC2-475C-B04E-6C98C87819F6 Q37871915-BEEEDD3E-4B60-4F45-9C88-E595D1AD88EC Q38034956-9A1B724B-9530-4D8B-9638-19D94362202E Q38040684-195B30C1-2052-4D57-B330-22EE880C95B3 Q38134094-29B6A27D-34C9-49F6-8DB5-BA14C26AFBCA Q38176862-1BDAF268-3F5A-47FE-B32B-CBF7CE3A0153 Q38207580-3A2FA49D-1BDE-45D5-A21B-8C06926B1541 Q38208982-80C24DBA-5DB6-429A-83F8-1FCA3E86ED38 Q38312367-7F21F200-5103-4A17-AEE8-5547C5E1CDC7 Q38737416-8817F125-47DF-4D8B-BB5E-1028C9A20034

P2860

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

http://www.wikidata.org/entity/Q37210960

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

[18F]fluorodeoxyglucose positr ...... during mTOR inhibitor therapy.

@en

[18F]fluorodeoxyglucose positr ...... during mTOR inhibitor therapy.

@nl

type

label

[18F]fluorodeoxyglucose positr ...... during mTOR inhibitor therapy.

@en

[18F]fluorodeoxyglucose positr ...... during mTOR inhibitor therapy.

@nl

prefLabel

[18F]fluorodeoxyglucose positr ...... during mTOR inhibitor therapy.

@en

[18F]fluorodeoxyglucose positr ...... during mTOR inhibitor therapy.

@nl

P1433

Q37210960-5E213538-EF7C-461B-9784-021F0842B661

P1476

Q37210960-7DBDEFDD-8071-415D-859A-0BE319BAEFA3

P2093

Q37210960-094964F7-52E0-4F0B-BDFF-ADB269620BAB

Q37210960-1B039AF2-9A89-4DB8-9EF7-642F298355EC

Q37210960-21C6A34A-F618-4FB9-AF82-8C97B74026F6

Q37210960-28C4F059-A4CE-4683-B8C3-0B2348B7E64D

Q37210960-547861B7-752C-44FA-B769-5E19269C8505

Q37210960-63BCB5DD-0F51-41FE-8D98-E9344B62E3D8

Q37210960-A6F74FBE-1912-4C7C-802A-E7FBE253272D

Q37210960-B968D7E3-03C2-45D5-9CCC-DFA03DCF18C9

Q37210960-C6BAD874-E677-4D86-A83D-F2C9DC72D3A8

P2860

Q37210960-12773491-FA70-4A2B-8EB7-457FFABDBB58

Q37210960-195BE841-33F9-4EB6-AC02-2E80508381E7

Q37210960-2217BAC0-3504-4F53-91F1-44C5521B58F7

Q37210960-2424A193-2660-4866-9C98-C45AF31C4631

Q37210960-24AB2D54-84D4-4A28-94A0-9EC8C8656FC5

Q37210960-27E89EF3-4893-48D7-8236-82F83E812A47

Q37210960-2A2D893F-AEAC-4ECE-B5C6-556D38750193

Q37210960-371B366D-3763-4890-8B7D-086F8EAC1268

Q37210960-475AAD64-532D-485E-B988-83F52A84BEF9

Q37210960-4C8FB7C7-B130-40F7-B450-7B0AE3807264

P304

Q37210960-0F01163F-311D-434A-B3E6-749F26397058

P31

Q37210960-0031D536-D24A-4B79-8C10-2B96CA45AA04

P356

Q37210960-7128B836-0B2D-459E-8F34-2509D2EB414F

P407

Q37210960-F9476E6F-0733-48FA-8B34-C583589745BB

P433

Q37210960-39F13F7B-0099-4F1B-9490-6E6CAD6835F2

P478

Q37210960-8AA6BCC6-8CB7-4BFB-985A-75AC158F3C24

P50

Q37210960-01888AAA-2E64-4B53-A272-071A67BBD245

Q37210960-D198687B-A6B0-4CAD-86DE-ADCC2C045FCB

P577

Q37210960-33CF46B0-2CD0-4EDE-9595-0867C5DA8E62

P698

Q37210960-39809432-F6B4-4BAB-A8C7-410882E10016

P932

Q37210960-C2CCD64B-810D-4C6A-8C5B-B43CFDC3DBC3

P356

JCO.2008.18.8383

P1433

Journal of Clinical Oncology

P1476

[18F]fluorodeoxyglucose positr ...... during mTOR inhibitor therapy

@en

P2093

Antonio Jimeno

http://www.w3.org/2001/XMLSchema#string

Chris Endres

http://www.w3.org/2001/XMLSchema#string

Dan Laheru

http://www.w3.org/2001/XMLSchema#string

Dongweon Song

http://www.w3.org/2001/XMLSchema#string

Heather Jacene

http://www.w3.org/2001/XMLSchema#string

Martin G Pomper

http://www.w3.org/2001/XMLSchema#string

Richard Wahl

http://www.w3.org/2001/XMLSchema#string

Wells A Messersmith

http://www.w3.org/2001/XMLSchema#string

Wen Wee Ma

http://www.w3.org/2001/XMLSchema#string

P2860

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

mTOR and cancer: insights into a complex relationship

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Akt stimulates aerobic glycolysis in cancer cells

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

P304

2697-2704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.18.8383

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Felip Vilardell

P577

2009-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19380450

http://www.w3.org/2001/XMLSchema#string

P932

2689846

http://www.w3.org/2001/XMLSchema#string